Insight Molecular Diagnostics Inc. (IMDX) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Current Price
$5.47
Price Target
$10.50
Target Range
$9.00 — $12.00
Analyst Rating
Buy
Forward P/E—
Trailing P/E-1.2x
Forward PEG—
Implied Growth+57.9%
Median Target$10.50
Analyst Spread28.6%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$9
+64.5%
Consensus
$11
+92.0%
Bull Case
$12
+119.4%
IMDX Price Target Analysis
Updated March 5, 2026As of March 5, 2026, Insight Molecular Diagnostics Inc. (IMDX) has a Wall Street consensus price target of $10.50, based on estimates from 11 covering analysts. With the stock currently trading at $5.47, this represents a potential upside of +92.0%. The company has a market capitalization of $95M.
Analyst price targets range from a low of $9.00 to a high of $12.00, representing a 29% spread in expectations. The median target of $10.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 7 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, IMDX trades at a trailing P/E of -1.2x. Analysts expect EPS to grow +57.9% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+40.9%
Avg Forward P/E42.0x
Peers with Coverage5 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
| IMDXInsight Molecular Diagnostics Inc. | $95M | $5.47 | $10.50 | +92.0% | Buy | — | 11 |
 CAICaris Life Sciences, Inc. | $33.2B | $19.86 | $31.33 | +57.8% | Buy | 62.1x | 6 |
 VCYTVeracyte, Inc. | $2.9B | $36.27 | $47.25 | +30.3% | Buy | 22.0x | 20 |
 ADPTAdaptive Biotechnologies Corporation | $2.5B | $16.44 | $21.25 | +29.3% | Buy | — | 17 |
 NAUTNautilus Biotechnology, Inc. | $331M | $2.62 | $2.50 | -4.6% | Buy | — | 5 |
 CDIOCardio Diagnostics Holdings, Inc. | $141M | $5.26 | — | — | — | — | — |
 SEERSeer, Inc. | $103M | $1.85 | — | — | Hold | — | 4 |
 ASBPAspire Biopharma Holdings, Inc. | $63M | $1.32 | — | — | — | — | — |
 YDESYD Bio Limited Ordinary Shares | $35M | $8.45 | — | — | — | — | — |
 AIMDAinos, Inc. | $7M | $1.51 | — | — | — | — | — |
Upside Potential Comparison
IMDXCAIVCYTADPTNAUTSee IMDX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IMDX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare IMDX vs LLY
See how IMDX stacks up against sector leader Eli Lilly and Company.
Start ComparisonFrequently Asked Questions
What is the IMDX stock price target for 2026?
The consensus Wall Street price target for IMDX is $10.5, representing 92.0% upside from the current price of $5.47. With 11 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is IMDX a buy, sell, or hold?
IMDX has a consensus rating of "Buy" based on 11 Wall Street analysts. The rating breakdown is predominantly bullish, with 7 Buy/Strong Buy ratings. The consensus 12-month price target of $10.5 implies 92.0% upside from current levels.
Is IMDX stock overvalued or undervalued?
IMDX's current price is $5.47 with a consensus target of $10.5 (92.0% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can IMDX stock go?
The most bullish Wall Street analyst has a price target of $12 for IMDX, while the most conservative target is $9. The consensus of $10.5 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover IMDX stock?
IMDX is moderately covered, with 11 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 4 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the IMDX stock forecast?
The 12-month IMDX stock forecast based on 11 Wall Street analysts shows a consensus price target of $10.5, with estimates ranging from $9 (bear case) to $12 (bull case). The median consensus rating is "Buy".
Should I buy IMDX stock?
Wall Street analysts are very optimistic on IMDX, with a "Buy" consensus rating and $10.5 price target (92.0% upside). 7 of 11 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do IMDX price targets vary so much?
IMDX analyst price targets range from $9 to $12, a 29% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $10.5 consensus represents the middle ground.